Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Adkins

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Oral Oncology|October 6, 2014
Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'Douglas Adkins, Jessica Ley
The New England Journal of Medicine|September 17, 2025
Perioperative Pembrolizumab in Head and Neck Cancer. ReplyRavindra Uppaluri, Robert I Haddad, Douglas Adkins
Cancer Journal (Sudbury, Mass.)|September 27, 2022
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell CarcinomaDouglas Adkins, Jessica Ley, Jared Cohen, et al.
Transplantation|July 23, 2009
Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host diseaseDouglas Adkins, Voravit Ratanatharathorn, Harry Yang, et al.
Current Otorhinolaryngology Reports|August 22, 2022
Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck CancerShin Saito, Hirofumi Shibata, Douglas Adkins, et al.
Ecancermedicalscience|December 2, 2014
Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinomaJessica Ley, Tanya Wildes, Samir El-Mofty, et al.
The Lancet. Oncology|June 8, 2024
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trialDouglas Adkins, Jessica C Ley, Jingxia Liu, et al.
JCO Oncology Advances|August 20, 2025
Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II TrialDouglas Adkins, Jessica C Ley, Jingxia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?Douglas Adkins, Jessica Ley, Tanya M Wildes, et al.
Medical Oncology (Northwood, London, England)|January 13, 2017
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxelJessica Ley, Tanya M Wildes, Kristin Daly, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Oral Oncology|October 6, 2014
Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'Douglas Adkins, Jessica Ley
The New England Journal of Medicine|September 17, 2025
Perioperative Pembrolizumab in Head and Neck Cancer. ReplyRavindra Uppaluri, Robert I Haddad, Douglas Adkins
Cancer Journal (Sudbury, Mass.)|September 27, 2022
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell CarcinomaDouglas Adkins, Jessica Ley, Jared Cohen, et al.
Transplantation|July 23, 2009
Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host diseaseDouglas Adkins, Voravit Ratanatharathorn, Harry Yang, et al.
Current Otorhinolaryngology Reports|August 22, 2022
Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck CancerShin Saito, Hirofumi Shibata, Douglas Adkins, et al.
Ecancermedicalscience|December 2, 2014
Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinomaJessica Ley, Tanya Wildes, Samir El-Mofty, et al.
The Lancet. Oncology|June 8, 2024
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trialDouglas Adkins, Jessica C Ley, Jingxia Liu, et al.
JCO Oncology Advances|August 20, 2025
Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II TrialDouglas Adkins, Jessica C Ley, Jingxia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?Douglas Adkins, Jessica Ley, Tanya M Wildes, et al.
Medical Oncology (Northwood, London, England)|January 13, 2017
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxelJessica Ley, Tanya M Wildes, Kristin Daly, et al.
Pageof 9